

EMA/80737/2021

European Medicines Agency decision P/0063/2021

of 18 February 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rimegepant (EMEA-002812-PIP02-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0063/2021

of 18 February 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rimegepant (EMA-002812-PIP02-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Biohaven Pharmaceuticals, Inc. on 13 July 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for rimegepant, orodispersible tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for rimegepant, orodispersible tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for rimegepant, orodispersible tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Biohaven Pharmaceuticals, Inc., 215 Church Street, CT 06510 - New Haven, United States.

EMA/PDCO/610920/2020
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002812-PIP02-20

Scope of the application

Active substance(s):

Rimegepant

Condition(s):

Treatment of migraine headaches

Pharmaceutical form(s):

Orodispersible tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Biohaven Pharmaceuticals, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Biohaven Pharmaceuticals, Inc. submitted for agreement to the European Medicines Agency on 13 July 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 18 August 2020.

Supplementary information was provided by the applicant on 26 October 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of migraine headaches

- the paediatric population from birth to less than 6 years of age;
- orodispersible tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of migraine headaches

2.1.1. Indication(s) targeted by the PIP

Treatment of migraine attacks in children and adolescents

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Orodispersible tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age appropriate orodispersible tablet.
Non-clinical studies	0	Not applicable.
Clinical studies	3	Study 2 Open-label, single dose pharmacokinetic and tolerability study of rimegepant in paediatric subjects from 6 years to less than 12 years of age with a history of migraine headache including assessment of palatability of the formulation. Study 3 Double-blind, placebo-controlled, group sequential placebo-controlled

		study to assess the efficacy and safety of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents from 6 to less than 18 years of age. Study 4 Open-label study to assess the safety and tolerability of long term use of rimegepant taken up to once per day by children and adolescents (from 6 to less than 18 years of age) with migraine.
Extrapolation, modelling and simulation studies	1	Study 5 Population PK model based on adult data to establish paediatric doses to be used in paediatric studies 1, 2 and 3 and confirmation of appropriateness of these doses.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes